PARP-ингибиторы при новообразованиях женской репродуктивной системы
- Авторы: Покатаев ИА1, Тюляндин СА1
-
Учреждения:
- ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России
- Выпуск: Том 19, № 2 (2017)
- Страницы: 10-15
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/27128
- ID: 27128
Цитировать
Полный текст
Аннотация
Ферменты PARP-1 и PARP-2 участвуют в работе одной из шести известных систем репарации повреждений ДНК - эксцизионной репарации азотистых оснований. Ингибирование PARP нарушает работу эксцизионной репарации, что в условиях дефицита функции другого пути репарации ДНК - гомологичной рекомбинации - приводит к апоптозу опухолевых клеток. Одной из наиболее частых причин нарушения работы гомологичной рекомбинации является потеря функции белков BRCA1 или BRCA2 за счет инактивирующих мутаций, что делает группу PARP-ингибиторов наиболее эффективной именно при опухолях с герминальными или соматическими мутациями BRCA. В настоящей работе обсуждаются различия PARP-ингибиторов между собой (олапариба, нирапариба, велипариба, рукапариба и талазопариба), результаты их клинического изучения при опухолях женской репродуктивной системы, токсичность при применении этих препаратов в монорежиме и комбинации с цитотоксическими препаратами, а также данные о регистрации указанных препаратов в России и других странах.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
И А Покатаев
ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России
Email: pokia@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» 115478, Россия, Москва, Каширское ш., д. 23
С А Тюляндин
ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава Россиипроф., зав. отд-нием клинической фармакологии и химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» 115478, Россия, Москва, Каширское ш., д. 23
Список литературы
- Cseh A.M, Fábián Z, Sümegi B, Scorrano L. Poly(adenosine diphosphate - ribose) polymerase as therapeutic target: lessons learned from its inhibitors. Oncotarget 2017.
- Herceg Z, Wang Z.Q. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001; 422 (1-2): 97-110.
- Liu Y, Prasad R, Beard W.A et al. Coordination of Steps in Single - nucleotide Base Excision Repair Mediated by Apurinic/Apyrimidinic Endonuclease 1 and DNA Polymerase b. J Biol Chem 2007; 282 (18): 13532-41.
- Amé J.C, Rolli V, Schreiber V et al. PARP-2, A novelmammalian DNA damage dependent poly(ADP-ribose) polymerase. J Biol Chem 1999; 274: 17860-8.
- Ba X, Garg N.J. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 2011; 178: 946-55.
- Mortusewicz O, Amé J.C, Schreiber V et al. Feedback - regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 2007; 35 (22): 7665-75.
- Okano S, Lan L, Caldecott K.W et al. Spatial and temporal cellular responses to single - strand breaks in human cells. Mol Cell Biol 2003; 23 (11): 3974-81.
- Schreiber V, Amé J.C, Dollé P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277 (25): 23028-36.
- Farmer H, Mc Cabe N, Lord C.J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
- The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian Carcinoma. Nature 2011; 474: 609615.
- Chernikova S, Game J, Brown J. Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther 2012; 13 (2): 61-8.
- Dedes K.J, Wilkerson P.M, Wetterskog D et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10 (8): 1192-9.
- Murai J, Huang S.N, Das B.B et al. Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72 (21): 5588-99.
- Pommier Y, O'Connor M.J, de Bono J et al. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 2016; 8 (362): 362ps17.
- Корман Д.Б. Основы противоопухолевой химиотерапии. М.: Практическая медицина, 2006.
- Murai J, Huang S.N, Renaud A et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014; 13 (2): 433-43.
- Krishnakumar R, Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24.
- Kaufman B, Shapira-Frommer R, Schmutzler R et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. J Clin Oncol 2015; 33 (3): 244250.
- Покатаев И.А., Стенина М.Б., Чития Л.В. и др. Ретроспективный анализ эффективности химиотерапии при платинорезистентном и платинорефрактерном раке яичников. Вестн. РОНЦ. 2009; 20 (2): 34-40.
- Committee for Medicinal Products for Human Use. Lynparza (olaparib). 23 October 2014. EMA/CHMP/632090/2014. http://www. ema.europa. eu/ema/ index.jsp?curl =pages/medicines/human/medicines/003726/ smops/ Positive/human_smop_ 000744.jsp&mid= WC0b01ac058001d127
- Ledermann J, Harter P, Gourley C et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N Engl J Med 2012; 366: 1382-92.
- Ledermann J, Harter P, Gourley C et al. Overall survival (OS) in patients (pts) with platinum - sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. J Clin Oncol 2016; 34 (Suppl.; abstr 5501).
- Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15 (8): 852-61.
- Pujade-Lauraine E, Ledermann J.A, Penson R.T et al; Treatment with olaparib monotherapy in the maintenance setting significantly improves progression - free survival in patients with platinum - sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study. 2017 Society of Gynecologic Oncologists Annual Meeting. Abstract LBA2. Presented March 14, 2017.
- Robson M, Seock-Ah Im, Senkus E et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017.
- Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 2015; 353: 446-57.
- Rugo H.S, Olopade O.I, De Michele A et al. Adaptive randomization of veliparib - carboplatin treatment in breast cancer. N Engl J Med 2016; 375: 23-34.
- Geyer C.E, O'Shaughnessy J, Untch M et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple - negative breast cancer (TNBC). J Clin Oncol 2017; 35 (Suppl.; abstr 520).
- Mirza M.R, Monk B.J, Herrstedt J et al. Niraparib maintenance therapy in platinum - sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375 (22): 2154-64.
- Wahlberg E, Karlberg T, Kouznetsova E et al. Family - wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012; 30: 283-8.
- Shapira-Frommer R, Oza A.M, Domchek S.M et al. A phase II open - label, multicenter study of single - agent rucaparib in the treatment ofpatients with relapsed ovarian cancer and a deleterious BRCA mutation. J Clin Oncol 2015; 33 (Suppl.; abstr 5513).
- González Martin A. Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer? Lancet Oncol 2016. Swisher E.M, Lin K.K, Oza A.M, Scott C.L et al. Rucaparib in relapsed, platinum - sensitive high - grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open - label, phase 2 trial. Lancet Oncol 2016.
- US Food and Drug Administration (FDA). FDA grants accelerated approval to new treatment for advanced ovarian cancer (media release). 2016.
- De Bono J.S, Mina L.A, Gonzalez M et al. First - in - human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. In: ASCO Annual Meeting Proceedings, 2013.
- Jenner Z.B, Sood A.K, Coleman R.L. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol 2016; 12: 1439-5648, 61.
- De Bono J, Ramanathan R.K, Mina L et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov 2017; 7 (6): 620-9.
- Turner N.C, Telli M.L, Rugo H.S et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). J Clin Oncol 2017; 35 (Suppl.; abstr 1007).
- Kaye S.B, Lubinski J, Matulonis U et al. Phase II, open - label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADPribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-9.
- Bixel K, Hays J.L. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 2015; 8: 127-35.
- Ricks T.K, Chiu H.J, Ison G et al. Successes and challenges of PARP inhibitors in cancer therapy. Front Oncol 2015; 5: 222.
- Puhalla S, Beumer J.H, Pahuja S et al. Final results of a phase 1 study of single - agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum - refractory ovarian, or basal - like breast cancer (BRCA-wt). In: ASCO Annual Meeting Proceedings, 2014.
- Coleman R.L, Sill M.W, Bell - Mc Guinn K et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 137: 386-91.
- Kummar S, Kinders R, Gutierrez M.E et al. Phase 0 clinical trial of the poly (ADPribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27: 2705-11.
- Swisher E.M, Lin K.K, Oza A.M et al. Rucaparib in relapsed, platinum - sensitive high - grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open - label, phase 2 trial. Lancet Oncol 2017; 18 (1): 75-87.
- Lin K, Sun J, Maloney L et al. 2701 quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. Eur J Cancer 2015; 51: S531-2.
- Sun J.X, Frampton G, Wang K et al. A computational method for somatic versus germline variant status determination from targeted next - generation sequencing of clinical cancer specimens without a matched normal control. Cancer Res 2014; 74: 1893.
- Coleman R.L, Swisher E.M, Oza A.M et al. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: a phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). In: ASCO Annual Meeting Proceedings, 2016.
- Swisher E.M, Mc Neish I.A, Coleman R.L et al. ARIEL 2/3: an integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. In: ASCO Annual Meeting Proceedings, 2014
- Telli M.L, Jensen K.C, Vinayak S et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple - negative and BRCA1/2 mutation - associated breast cancer with assessment of a tumorbased measure of genomic instability: PrECOG 0105. J Clin Oncol 2015; 33: 1895-901.
- Abkevich V, Timms K.M, Hennessy B.T et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107: 1776-82.